Implanted Monitor Alerting to Reduce Treatment Delay in Patients With Acute Coronary Syndrome Events.


Journal

Journal of the American College of Cardiology
ISSN: 1558-3597
Titre abrégé: J Am Coll Cardiol
Pays: United States
ID NLM: 8301365

Informations de publication

Date de publication:
22 10 2019
Historique:
received: 29 03 2019
revised: 16 06 2019
accepted: 17 07 2019
entrez: 19 10 2019
pubmed: 19 10 2019
medline: 2 6 2020
Statut: ppublish

Résumé

Increased pre-hospital delay during acute coronary syndrome (ACS) events contributes to worse outcome. The purpose of this study was to assess the effectiveness of an implanted cardiac monitor with real-time alarms for abnormal ST-segment shifts to reduce pre-hospital delay during ACS events. In the ALERTS (AngeLmed Early Recognition and Treatment of STEMI) pivotal study, subjects at high risk for recurrent ACS events (n = 907) were randomized to control (Alarms OFF) or treatment groups for 6 months, after which alarms were activated in all subjects (Alarms ON). Emergency department (ED) visits with standard-of-care cardiac test results were independently adjudicated as true- or false-positive ACS events. Alarm-to-door (A2D) and symptom-to-door (S2D) times were calculated for true-positive ACS ED visits triggered by 3 possible prompts: alarm only, alarms + symptoms, or symptoms only. The Alarms ON group showed reduced delays, with 55% (95% confidence interval [CI]: 46% to 63%) of ED visits for ACS events <2 h compared with 10% (95% CI: 2% to 27%) in the Alarms OFF group (p < 0.0001). Results were similar when restricted to myocardial infarction (MI) events. Median pre-hospital delay for MI was 12.7 h for Alarms OFF and 1.6 h in Alarms ON subjects (p < 0.0089). Median A2D delay was 1.4 h for asymptomatic MI. Median S2D delay for symptoms-only MI (no alarm) in Alarms ON was 4.3 h. Intracardiac monitoring with real-time alarms for ST-segment shift that exceeds a subject's self-normative ischemia threshold level significantly reduced the proportion of pre-hospital delays >2 h for ACS events, including asymptomatic MI, compared with symptoms-only ED visits in Alarms OFF. (AngeLmed for Early Recognition and Treatment of STEMI [ALERTS]; NCT00781118).

Sections du résumé

BACKGROUND
Increased pre-hospital delay during acute coronary syndrome (ACS) events contributes to worse outcome.
OBJECTIVES
The purpose of this study was to assess the effectiveness of an implanted cardiac monitor with real-time alarms for abnormal ST-segment shifts to reduce pre-hospital delay during ACS events.
METHODS
In the ALERTS (AngeLmed Early Recognition and Treatment of STEMI) pivotal study, subjects at high risk for recurrent ACS events (n = 907) were randomized to control (Alarms OFF) or treatment groups for 6 months, after which alarms were activated in all subjects (Alarms ON). Emergency department (ED) visits with standard-of-care cardiac test results were independently adjudicated as true- or false-positive ACS events. Alarm-to-door (A2D) and symptom-to-door (S2D) times were calculated for true-positive ACS ED visits triggered by 3 possible prompts: alarm only, alarms + symptoms, or symptoms only.
RESULTS
The Alarms ON group showed reduced delays, with 55% (95% confidence interval [CI]: 46% to 63%) of ED visits for ACS events <2 h compared with 10% (95% CI: 2% to 27%) in the Alarms OFF group (p < 0.0001). Results were similar when restricted to myocardial infarction (MI) events. Median pre-hospital delay for MI was 12.7 h for Alarms OFF and 1.6 h in Alarms ON subjects (p < 0.0089). Median A2D delay was 1.4 h for asymptomatic MI. Median S2D delay for symptoms-only MI (no alarm) in Alarms ON was 4.3 h.
CONCLUSIONS
Intracardiac monitoring with real-time alarms for ST-segment shift that exceeds a subject's self-normative ischemia threshold level significantly reduced the proportion of pre-hospital delays >2 h for ACS events, including asymptomatic MI, compared with symptoms-only ED visits in Alarms OFF. (AngeLmed for Early Recognition and Treatment of STEMI [ALERTS]; NCT00781118).

Identifiants

pubmed: 31623762
pii: S0735-1097(19)37374-7
doi: 10.1016/j.jacc.2019.07.084
pii:
doi:

Banques de données

ClinicalTrials.gov
['NCT00781118']

Types de publication

Clinical Trial, Phase III Journal Article Multicenter Study Randomized Controlled Trial Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

2047-2055

Commentaires et corrections

Type : CommentIn

Informations de copyright

Copyright © 2019. Published by Elsevier Inc.

Auteurs

David R Holmes (DR)

Department of Cardiovascular Medicine, Mayo Clinic, Rochester, Minnesota. Electronic address: holmes.david@mayo.edu.

Mitchell W Krucoff (MW)

Duke University Medical Center and Duke Clinical Research Institute, Durham, North Carolina.

Chris Mullin (C)

North American Science Associates, Inc., Toledo, Ohio.

Ghiath Mikdadi (G)

Heart Clinic of Hammond, Hammond, Louisiana.

Dale Presser (D)

Innovative Medical Research LLC, Covington, Louisiana.

David Wohns (D)

Division of Cardiovascular Medicine, Grand Rapids, Michigan.

Andrew Kaplan (A)

Banner Heart Hospital, Mesa, Arizona.

Allen Ciuffo (A)

Sentara Healthcare Norfolk, Norfolk, Virginia.

Arthur L Eberly (AL)

Greenville Memorial Hospital, Greenville, South Carolina.

Bruce Iteld (B)

Louisiana Heart Center, Hammond, Louisiana.

David R Fischell (DR)

Angel Medical Systems, Eatontown, New Jersey.

Tim Fischell (T)

Angel Medical Systems, Eatontown, New Jersey.

David Keenan (D)

Angel Medical Systems, Eatontown, New Jersey.

M Sasha John (MS)

Angel Medical Systems, Eatontown, New Jersey.

C Michael Gibson (CM)

Division of Cardiovascular Medicine, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH